3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
High-risk Leukemias
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Oxaliplatin
200
Capecitabine
116
S 1 (combination)
106
Fluorouracil
105
Docetaxel
100
Cisplatin
88
Leucovorin
75
Paclitaxel
71
Irinotecan
68
apatinib
43
sintilimab
42
Drug Therapy
42
Surgical Procedures, Operative
37
Hyperthermic Intraperitoneal Chemotherapy
34
pembrolizumab
32
Radiotherapy
31
Trastuzumab
30
Gastrectomy
23
Nivolumab
22
Epirubicin
22
Tegafur
21
Bevacizumab
21
XELOX
20
titanium silicide
19
camrelizumab
19
tislelizumab
17
Ramucirumab
17
Carboplatin
16
Neoadjuvant Therapy
15
Endoscopic Mucosal Resection
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Stomach Neoplasms
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled